Shares of Gilead Sciences Inc. slid 4.80% to $97.88 Tuesday, on what proved to be an all-around poor trading session for the ...

Shares of Gilead Sciences Inc. GILD slid 3.09% to $103.25 Thursday, on what proved to be an all-around favorable trading ...

Shares of Gilead Sciences Inc. GILD rallied 2.24% to $106.54 Wednesday, on what proved to be an all-around favorable trading ...

Gilead Sciences Down Nearly 5%, On Track for Largest Percent Decrease Since January 2024 — Data Talk Gilead Sciences, Inc. (GILD) is currently at $97.68, down $5.14 or 4.99% --Would be lowest close ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

The subdued stock price reaction suggests that Gilead Sciences, Inc.'s (NASDAQ:GILD) strong earnings didn't offer any surprises. We think that investors have missed some encouraging factors ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...